Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ranbaxy Laboratories (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), has signed an agreement with Cipher Pharmaceuticals to launch Absorica in fourth quarter of 2012, in the US.
Subscribe to our email newsletter
As per the agreement, Ranbaxy will pay royalties on net sales of Absorica to Cipher.
Ranbaxy Americas senior vice president and regional director Venkat Krishnan said, "Absorica is a critical milestone in our commitment to serve the dermatology community and will be the flagship brand for Ranbaxy’s specialized dermatology sales force."
Cipher president and CEO Larry Andrews said the company looks forward to work with Ranbaxy Laboratories in preparation for the upcoming US launch of the product through its dermatology sales force.
Absorica is a novel, patented brand formulation of the acne medication isotretinoin, developed by Cipher, for the treatment of severe recalcitrant nodular acne.